For & Against
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
What's Next
The IHC deal is done — RBI approved in March 2026, SEBI in April, and the first tranche of $602M has landed. What the market does not yet have is proof that the capital translates into cheaper borrowing. The next six months will answer that.
The market will focus most intensely on Q1 FY2027 earnings. Both the bull and bear cases anchor on the same number — incremental cost of borrowings. Two quarters showing new borrowing below 7.5% would confirm the mechanical earnings uplift. A credit rating upgrade from AA to AA+ would provide external validation and accelerate the repricing. The PIL remains the wildcard — no news since November 2025, but the Supreme Court's order for CBI to file an FIR has not been withdrawn.
For / Against / My View
For
A 270bps reduction in cost of funds on $4,555M of borrowings adds ~$117M to pre-tax profit — nearly doubling normalized pre-tax earnings of ~$181M. This is not growth-dependent; it is a mechanical result of IHC's sovereign-backed credit profile enabling higher ratings and cheaper bank lines. The first tranche of $602M has already been received.
Evidence: 270bps guided cost reduction on $4,555M stock borrowings, with every 100bps = ~$45M pre-tax. Normalized annual PAT ~$136M on run-rate quarterly profits of $33–36M across 13 consecutive normal quarters.
Management took $490M of provisions in Q2 FY2025 to deliver IHC a clean balance sheet. GNPA dropped from 2.68% to 1.30% in a single quarter; NNPA fell to 0.80%. The legacy book has $480M of guided net cash recoveries over three years — free capital that funds the growth pivot without additional dilution.
Evidence: GNPA 1.30% (down from 2.68%), NNPA 0.80% — lowest in six years. Legacy book yielded 11.7% IRR since FY2019 with 1.5% cumulative credit cost. $480M net cash recoveries guided over 3 years.
IHC — a ~$240B market cap Abu Dhabi sovereign-linked entity — committed $943M for 41.2% after exhaustive regulatory due diligence. RBI approved in March 2026; SEBI in April 2026. The open offer provides a hard price floor. IHC is becoming the controlling promoter, locking in its capital for years.
Evidence: IHC acquiring 41.2% at $1.48/share ($943M total). RBI/SEBI approvals received. Open offer at $1.63. First tranche of $602M already received.
Bull price target: $2.67 (0.9x projected book of ~$2.99) over 18–24 months. Catalyst: first two quarterly earnings post-deal showing incremental cost of borrowings below 7.5%.
Against
IHC acquired 41.2% via preferential allotment at $1.48/share — a 49% discount to $2.88 book value — inflating share count 3.3x from 44.5 Cr to 145.2 Cr. Every percentage point of ROE recovery is spread across 3.3x more shares. A further 7 Cr stock options at $1.61 add 6% dilution on top.
Evidence: QIP at $1.60 and IHC preferential at $1.48, both well below $2.88 book. Management owns under 1%. Post-dilution normalized ROE falls from 5.9% to 4.1%, pushing fair P/B even lower than today's 0.53x.
Revenue has been stuck at $906–928M since FY2022. Management asks the market to believe it can triple branches, quadruple products, and enter businesses where it has zero origination history. The company has demonstrated it can shrink; it has never demonstrated it can grow.
Evidence: Revenue $1,186M (FY2022) to $1,015M (FY2025), flat. 2.5% ROA target requires simultaneously lower cost of funds, stable credit costs, and controlled opex as the branch network triples — a three-variable optimization with no margin for error.
Of 10 identifiable targets since Q2 FY2024, 4 were missed and 3 were revised. AUM target of $10.7B by FY2026 reached only $6.6B — a 38% miss. ROE targets migrated four times in two years. The 270bps cost-of-funds reduction is another forward promise from a management team with a 43% hit rate.
Evidence: Guidance tracker shows 3 met versus 4 missed on assessable targets. ROE target migrated four times. "Say what we do, do what we say" is contradicted by the scorecard.
Bear downside target: $1.01 (0.35x book) over 12–18 months. Trigger: Q1 or Q2 FY2027 earnings showing incremental borrowing costs still above 8.5% or quarterly disbursals below $128M.
The Tensions
1. Cost of funds: mechanical uplift or the next broken promise?
Bull says the 270bps reduction is not a management growth target but a structural consequence of IHC's credit profile — sovereign parentage yields higher ratings and cheaper bank lines, mechanically adding ~$117M to pre-tax profit. Bear says this is another forward promise from a team that has hit only 43% of its guidance, and no credit rating upgrade has been announced despite the deal closing. Both cite the same number: 270bps on $4,555M of borrowings. This resolves on Q4 FY2026 and Q1 FY2027 incremental borrowing costs — below 7.5% confirms the thesis; above 8.5% for two quarters breaks it.
2. The dilution: franchise validation or permanent value transfer?
Bull says IHC's $943M commitment at $1.48/share — after full regulatory due diligence by a ~$240B sovereign entity — is the strongest external validation that this platform has franchise value beyond its book. Bear says the same transaction at a 49% discount to $2.88 book value inflates share count 3.3x, dropping post-dilution normalized ROE from 5.9% to 4.1% and making the current 0.53x P/B mathematically fair rather than cheap. Both cite the same deal, same numbers, opposite conclusions. This resolves on whether post-dilution ROE crosses 10% within 18 months — proving IHC's capital is accretive, not extractive.
My View
I'd lean cautiously toward the For side, but the lean is narrow. The IHC deal is real — regulatory approvals secured, $602M received, and zero shares tendered in the open offer signals shareholders see upside beyond the offer price. The first tension — cost of funds — is what tips the scale: the mechanism here is different from prior management misses because it depends on IHC's credit profile replacing the Indiabulls-era funding structure, not on management executing a growth plan from scratch. If the next two quarters of incremental borrowing cost come in below 7.5%, this stock reprices toward book value. The one condition that would flip my view: borrowing costs staying above 8.5% with no credit rating upgrade by September 2026 — that would mean the IHC thesis itself is broken, not just delayed.